TIS 0.00% 0.0¢ tissue therapies limited

TIS - Competitive landscape, page-5

  1. 1,635 Posts.
    lightbulb Created with Sketch. 98
    Vitrogro is aimed at hard to heal wounds, sores, etc, and i dont think Polynovo is a direct competitor.
    Much bigger market for sores, etc, and growing fast.
    The good doctors research (as per link) on isolating the protein and the hype surrounding it will benefit TIS greatly as it shows there is a lot of interest for a quick and cheap product. TIS will be on the market in 2 years and as the doctor stated they are 5-10 years away.
    Still concerned over the TIS timeline and cashflow but at least they seem to be on the right track and with much better communication and vision.
    Its a pity the plonker who nearly ran TIS into the ground took so long to clear off.
 
watchlist Created with Sketch. Add TIS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.